CN1040321C - 吡喃-2-酮及5,6-二氢吡喃-2-酮、含有它们的药物组合物及其制药用途 - Google Patents

吡喃-2-酮及5,6-二氢吡喃-2-酮、含有它们的药物组合物及其制药用途 Download PDF

Info

Publication number
CN1040321C
CN1040321C CN93114470A CN93114470A CN1040321C CN 1040321 C CN1040321 C CN 1040321C CN 93114470 A CN93114470 A CN 93114470A CN 93114470 A CN93114470 A CN 93114470A CN 1040321 C CN1040321 C CN 1040321C
Authority
CN
China
Prior art keywords
hydroxyl
pyran
cyclopropyl
phenyl
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN93114470A
Other languages
English (en)
Chinese (zh)
Other versions
CN1090279A (zh
Inventor
S·泰斯里旺斯
C·-P·杨
J·W·施特罗巴哈
S·R·特纳
D·L·罗默洛
L·L·施卡列茨基
P·A·阿里斯托夫
R·B·加米尔
P·D·约翰逊
H·I·施库尼克
R·C·派帕
R·A·托马西
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Famasia And Upjohn
Pharmacia and Upjohn Co
Original Assignee
Famasia And Upjohn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Famasia And Upjohn filed Critical Famasia And Upjohn
Publication of CN1090279A publication Critical patent/CN1090279A/zh
Application granted granted Critical
Publication of CN1040321C publication Critical patent/CN1040321C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/32—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C07D309/38—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms one oxygen atom in position 2 or 4, e.g. pyrones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/96—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings spiro-condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • AIDS & HIV (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cosmetics (AREA)
CN93114470A 1992-11-13 1993-11-12 吡喃-2-酮及5,6-二氢吡喃-2-酮、含有它们的药物组合物及其制药用途 Expired - Lifetime CN1040321C (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US97534392A 1992-11-13 1992-11-13
US975,343 1992-11-13
US9087693A 1993-07-13 1993-07-13
US090,876 1993-07-13
US13064193A 1993-10-01 1993-10-01
US130,641 1993-10-01

Publications (2)

Publication Number Publication Date
CN1090279A CN1090279A (zh) 1994-08-03
CN1040321C true CN1040321C (zh) 1998-10-21

Family

ID=27376682

Family Applications (1)

Application Number Title Priority Date Filing Date
CN93114470A Expired - Lifetime CN1040321C (zh) 1992-11-13 1993-11-12 吡喃-2-酮及5,6-二氢吡喃-2-酮、含有它们的药物组合物及其制药用途

Country Status (26)

Country Link
EP (2) EP0668860B1 (da)
JP (1) JP3583127B2 (da)
KR (1) KR100314975B1 (da)
CN (1) CN1040321C (da)
AT (2) ATE290531T1 (da)
AU (1) AU687368B2 (da)
BR (1) BR9307451A (da)
CA (1) CA2145661C (da)
CZ (1) CZ291853B6 (da)
DE (2) DE69332292T2 (da)
DK (2) DK1203770T3 (da)
ES (2) ES2182837T3 (da)
FI (1) FI120399B (da)
GE (1) GEP20094660B (da)
HU (1) HU228126B1 (da)
IL (1) IL107556A (da)
LV (1) LV13088B (da)
MY (1) MY119031A (da)
NO (1) NO319914B1 (da)
NZ (1) NZ258013A (da)
PL (1) PL178653B1 (da)
PT (2) PT1203770E (da)
RU (1) RU2134691C1 (da)
SK (1) SK285001B6 (da)
WO (1) WO1994011361A1 (da)
ZA (1) ZA938019B (da)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0720607A1 (en) * 1993-09-17 1996-07-10 PHARMACIA & UPJOHN COMPANY Substituted tetronic acids useful for treating hiv and other retroviruses
JP3698435B2 (ja) * 1993-11-19 2005-09-21 パーク・デイビス・アンド・カンパニー プロテアーゼ阻害剤および抗ウイルス剤としての５，６−ジヒドロピロン誘導体
AU689158B2 (en) * 1993-11-19 1998-03-26 Parke, Davis & Company 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents
HUT77719A (hu) * 1993-11-19 1998-07-28 Parke, Davis & Co. Proteáz enzimeket gátló pironszármazékok és azokat hatóanyagként tartalmazó vírusellenes gyógyászati készítmények
EP0729466A1 (en) * 1993-11-19 1996-09-04 PARKE, DAVIS & COMPANY Pyrone derivatives as protease inhibitors and antiviral agents
US6005103A (en) * 1993-11-19 1999-12-21 Warner-Lambert Company Pyrone derivatives as protease inhibitors and antiviral agents
US5840751A (en) * 1993-11-19 1998-11-24 Warner-Lambert Company 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents
IL129871A (en) * 1994-05-06 2003-11-23 Pharmacia & Upjohn Inc Process for preparing 4-phenyl-substituted octanoyl-oxazolidin-2-one intermediates that are useful for preparing pyran-2-ones useful for treating retroviral infections
JPH11503416A (ja) * 1995-03-20 1999-03-26 ファルマシア・アンド・アップジョン・カンパニー Ｈｉｖおよび他のレトロウイルス病を治療するのに有用な置換テトロン酸
EP0909184B1 (en) * 1996-07-03 2003-09-17 PHARMACIA & UPJOHN COMPANY Targeted drug delivery using sulfonamide derivatives
CN1284763C (zh) * 1997-09-11 2006-11-15 法玛西雅厄普约翰美国公司 用于制备蛋白酶抑制剂的化合物
AU756965B2 (en) 1998-03-12 2003-01-30 Microbial Chemistry Research Foundation Benzofurylpyrone derivatives
EP1281399A3 (en) * 2001-08-01 2004-02-11 Warner-Lambert Company Dual inhibitors of wax ester and cholesteryl ester synthesis for inhibiting sebum production
DOP2003000641A (es) * 2002-05-10 2003-11-15 Pfizer Inhibidores de las arn polimerasa dependiente de arn del virus de las hepatitis c y composiciones y tratamiento que los usan
JP4638441B2 (ja) 2003-10-24 2011-02-23 ロンザ アーゲー ６，６，６−トリハロ−３，５−ジオキソヘキサン酸エステルの生産方法
EP2032551B9 (en) * 2006-06-16 2012-02-29 Pharma Mar, S.A. Antitumoral dihydropyran-2-one compounds
ES2442140T3 (es) 2007-12-20 2014-02-25 Pharma Mar S.A. Compuestos antitumorales
CN102177164B (zh) 2008-11-05 2015-02-11 科莱恩金融(Bvi)有限公司 利用烯丙醇/丙烯醛制备二烷基次膦酸、二烷基次膦酸酯和二烷基次膦酸盐的方法,以及它们的用途
DE102008055914A1 (de) 2008-11-05 2010-05-06 Clariant International Limited Verfahren zur Herstellung von mono-hydroxyfunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Acroleinen und ihre Verwendung
DE102008055916A1 (de) 2008-11-05 2010-05-06 Clariant International Limited Verfahren zur Herstellung von mono-hydroxyfunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Allylalkoholen und ihre Verwendung
EP2352740B1 (de) 2008-11-07 2014-09-24 Clariant Finance (BVI) Limited Verfahren zur herstellung von dialkylphosphinsäuren, -estern und -salzen mittels acrylsäurederivaten und ihre verwendung
DE102008056341A1 (de) 2008-11-07 2010-05-12 Clariant International Limited Verfahren zur Herstellung von monoaminofunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Acrylnitrilen und ihre Verwendung
DE102008056342A1 (de) 2008-11-07 2010-05-12 Clariant International Limited Verfahren zur Herstellung von Dialkylphosphinsäuren, -estern und -salzen mittels Acrylnitrilen und ihre Verwendung
DE102008056339A1 (de) 2008-11-07 2010-05-12 Clariant International Limited Verfahren zur Herstellung von mono-aminofunktionalisierten Dialkylphosphinsäuren, -estern und -salzen und ihre Verwendung
CN102171226B (zh) 2008-11-11 2015-02-11 科莱恩金融(Bvi)有限公司 利用烯丙基化合物制备单烯丙基官能化的二烷基次膦酸、其盐或酯的方法以及它们的用途
DE102008060036A1 (de) * 2008-12-02 2010-06-10 Clariant International Limited Verfahren zur Herstellung von mono-carboxyfunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Vinylester einer Carbonsäure und ihre Verwendung
DE102008060035A1 (de) 2008-12-02 2010-06-10 Clariant International Limited Verfahren zur Herstellung von mono-hydroxyfunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Vinylester einer Carbonsäure und ihre Verwendung
DE102008060535A1 (de) * 2008-12-04 2010-06-10 Clariant International Limited Verfahren zur Herstellung von mono-carboxyfunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Vinylether und ihre Verwendung
DE102008063627A1 (de) 2008-12-18 2010-06-24 Clariant International Limited Verfahren zur Herstellung von monohydroxyfunktionalisierten Dialkylphosphinsäuren,-estern und -salzen mittels Ethylenoxid und ihre Verwendung
DE102008063668A1 (de) 2008-12-18 2010-07-01 Clariant International Limited Verfahren zur Herstellung von Alkylphosponsäuren, -estern und -salzen mittels Oxidation von Alkylphosphonigsäuren und ihre Verwendung
DE102008063642A1 (de) * 2008-12-18 2010-06-24 Clariant International Limited Verfahren zur Herstellung von monocarboxyfunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Alkylenoxiden und ihre Verwendung
ES2446666T3 (es) 2008-12-18 2014-03-10 Clariant Finance (Bvi) Limited Procedimiento para la preparación de ácidos etilen-dialquil-fosfínicos, o de sus ésteres y sales, mediante acetileno, y su utilización
DE102008064003A1 (de) 2008-12-19 2010-06-24 Clariant International Limited Verfahren zur Herstellung von mono-funktionalisierten Dialkylphosphinsäuren, -estern und -salzen und ihre Verwendung
DE102008064012A1 (de) 2008-12-19 2010-06-24 Clariant International Limited Halogenfreie Addukte von Alkylphosphonigsäurederivaten und diesterbildenden Olefinen, halogenfreie Verfahren zu deren Herstellung und ihre Verwendung
US20120202814A1 (en) * 2009-10-02 2012-08-09 Università Degli Studi Di Siena Compounds with ddx3 inhibitory activity and uses thereof
CN102690275A (zh) * 2011-03-25 2012-09-26 中国人民解放军第二军医大学 四氢呋喃并[3,4-c]吡喃酮类化合物及其制备方法和用途
CN103044375B (zh) * 2012-12-02 2015-08-12 大理学院 一种二氢吡喃酮化合物及其制备方法和药物用途
CN114835694B (zh) * 2022-05-25 2024-06-21 中国科学技术大学 一种在水介质中合成手性3，4-二氢-2h-吡喃类化合物的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989007939A2 (en) * 1988-03-01 1989-09-08 The Upjohn Company Coumarins to inhibit reverse transcriptase in humans

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1276654A (fr) * 1958-10-01 1961-11-24 Nouveaux dérivés de l'hydroxy-4-alpha-2-pyrone
FR1276645A (fr) * 1959-12-28 1961-11-17 Wild Heerbrugg Ag Objectif de microscope

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989007939A2 (en) * 1988-03-01 1989-09-08 The Upjohn Company Coumarins to inhibit reverse transcriptase in humans

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACT VOL.85,NO.27,1976.1.1 *

Also Published As

Publication number Publication date
CA2145661C (en) 2008-04-01
PT1203770E (pt) 2005-05-31
ES2182837T3 (es) 2003-03-16
IL107556A0 (en) 1994-02-27
CZ291853B6 (cs) 2003-06-18
WO1994011361A1 (en) 1994-05-26
AU5549394A (en) 1994-06-08
MY119031A (en) 2005-03-31
HU228126B1 (en) 2012-12-28
NO951899D0 (no) 1995-05-12
AU687368B2 (en) 1998-02-26
CN1090279A (zh) 1994-08-03
EP1203770A1 (en) 2002-05-08
FI120399B (fi) 2009-10-15
CZ107895A3 (en) 1995-12-13
DK0668860T3 (da) 2003-01-20
FI952302A0 (fi) 1995-05-11
SK285001B6 (sk) 2006-04-06
JP3583127B2 (ja) 2004-10-27
RU2134691C1 (ru) 1999-08-20
DE69332292D1 (de) 2002-10-17
ATE290531T1 (de) 2005-03-15
BR9307451A (pt) 1999-08-31
KR100314975B1 (ko) 2002-02-28
ZA938019B (en) 1995-04-28
SK61695A3 (en) 1995-10-11
PL178653B1 (pl) 2000-05-31
DK1203770T3 (da) 2005-05-23
LV13088B (en) 2004-01-20
DE69333771T2 (de) 2006-04-06
DE69332292T2 (de) 2003-05-28
EP0668860A1 (en) 1995-08-30
RU95112465A (ru) 1997-03-20
JPH08503216A (ja) 1996-04-09
CA2145661A1 (en) 1994-05-26
ATE223910T1 (de) 2002-09-15
EP0668860B1 (en) 2002-09-11
PT668860E (pt) 2003-01-31
KR950704290A (ko) 1995-11-17
GEP20094660B (en) 2009-03-25
NO319914B1 (no) 2005-10-03
HU9501411D0 (en) 1995-06-28
ES2237624T3 (es) 2005-08-01
IL107556A (en) 2001-08-08
NO951899L (no) 1995-07-12
FI952302A (fi) 1995-05-11
HUT71558A (en) 1995-12-28
NZ258013A (en) 1997-02-24
PL308998A1 (en) 1995-09-18
DE69333771D1 (de) 2005-04-14
EP1203770B1 (en) 2005-03-09

Similar Documents

Publication Publication Date Title
CN1040321C (zh) 吡喃-2-酮及5,6-二氢吡喃-2-酮、含有它们的药物组合物及其制药用途
CN1154642C (zh) 用于治疗逆转录病毒感染的化合物
CN1117291A (zh) 用于治疗逆转录病毒感染的4-羟基-吡喃-2-酮类衍生物
CN1036920C (zh) 含杂环碳酸衍生物
CN1279034C (zh) Dna－pk抑制剂
CN1207288C (zh) 逆病毒蛋白酶抑制化合物
CN1166658C (zh) 作为环加氧酶-2-抑制剂的4,5二芳基-3(2h)-呋喃酮衍生物
CN1053607A (zh) 用于治疗aids的人体免疫缺乏病毒蛋白酶的抑制剂
CN1545508A (zh) 1,2,4－三噁茂烷抗疟药
CN1775759A (zh) 二环类雄激素和孕甾酮受体调节化合物和方法
CN1016868B (zh) 5-芳烷基-4-烷氧基-2(5h)-呋喃酮制备方法
CN101052630A (zh) 取代的杂环化合物和其用途
CN1290833C (zh) 用于治疗梗塞和心绞痛的nhe－1抑制剂n－((3－氧代－2,3－二氢－1h－异吲哚－1－基)乙酰基)胍衍生物
CN1761657A (zh) Ep4受体拮抗剂
CN1234029A (zh) 色烯－3－羚酸衍生物
CN1617856A (zh) 取代的4－苯基四氢异喹啉、其制备方法、其用作药物的用途以及含有它们的药物
CN1747952A (zh) 治疗细胞增殖性疾病、视网膜病和关节炎的化合物和方法
CN1108935A (zh) 含有喹喔啉和核苷的组合物制剂
CN1191243C (zh) 用作抗炎剂的二氢苯并呋喃和相关化合物
CN1245169A (zh) 新的硝酮化合物,其制备方法以及含有它们的药物组合物
CN1214677A (zh) 作为环氧化酶－2抑制剂药物前体的二苯基1,2－二苯乙烯类化合物
CN1105711C (zh) 嘧啶衍生物
CN1646524A (zh) 用包括四唑的仲胺取代的苯并吡喃衍生物、其制备方法以及含有它们的药物组合物
CN1024663C (zh) 治疗气喘用的取代的四氢化萘类化合物的制备方法
CN1120538A (zh) 3-杂脂基和3-杂(芳基)脂基-2(1h)-喹诺酮衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CX01 Expiry of patent term

Expiration termination date: 20131112

Granted publication date: 19981021